<DOC>
	<DOCNO>NCT00136994</DOCNO>
	<brief_summary>To evaluate efficacy tolerability Ziprasidone IM oral agitate patient acute exacerbation schizophrenia</brief_summary>
	<brief_title>IM Oral Acute Exacerbation Schizophrenia ( BIZET Study )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Psychiatric : Diagnosis schizophrenia use DSMIV ( 295.xx ) . Patients enter hospital ( inpatient transfer higherdependency unit ) within previous seven day acute exacerbation psychotic symptom . PANSS &gt; 80 ( score Â³ 3 least three follow PANSS agitation item : anxiety , tension , hostility , excitement ) . CGIS Â³ 4 . Indication , base intensity/severity psychotic symptom , IM therapy . General : Male Female patient age 1860 year screen . Written inform consent participation . Female patient risk pregnancy must avoid remain pregnant ; adequate method contraception initiate continued . Psychiatric : Patients immediate risk commit harm self others Concurrent treatment antipsychotic agent baseline Patients receive depot antipsychotic medication within 21 day screen Treatment antidepressant mood stabilizer ( lithium , carbamazepine , valproic acid verapamil ) within two week screen Diagnosis substance abuse use DSMIV criterion within previous 12 month Positive urine drug screen screen amphetamine , cocaine opioids Alcohol and/or drug abuse screen Patients receive clozapine within 3 month prior screen due intolerance antipsychotic patient receive clozapine past two year refractoriness treatment Treatment investigational agent within previous six month Previous treatment ziprasidone Organic mental disease , include mental retardation History psychosurgery General : Patients history clinically significant and/or currently relevant hematological , renal ( include single kidney ) , hepatic , gastrointestinal , endocrine ( except current adequately treat hypo hyperthyroidism ) , pulmonary ( exclude chronic bronchitis , mild emphysema chronic obstructive pulmonary disease ) , dermatological , oncological , neurological disease , exclude tardive dyskinesia include form epilepsy ( febrile convulsion childhood acceptable ) . The patient know prior malignant disease eligible cure prior skin cancer ( exclude melanoma ) . Controlled Type II diabetes ( glucose &lt; 180 mg/100 ml screen baseline dietary oral hypoglycemic treatment ) consider significant medical illness would exclude subject study Patients history significant cardiovascular disease significant concurrent cardiovascular disease , include history uncontrolled hypertension ( supine diastolic pressure &gt; 95 mm Hg and/or supine systolic pressure &gt; 170 mm Hg without treatment ) Clinically significant ECG abnormality Patient QTc Â³ 450 msec Concomitant treatment medication prolong QT interval Patients serum K+ Mg++ outside normal range Confirmed clinically significant laboratory value . Known serological evidence HIV , acute chronic hepatitis ( transaminase level higher three time normal limit ) Patients intend donate blood blood product 4 week prior study , study 30 day study end Patients unable unlikely follow study protocol Pregnant lactate woman Patients history neuroleptic malignant syndrome develop administration antipsychotic compound Known hypersensitivity ziprasidone lactose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>